Ashley Chan

Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC: © stock.adobe.com Adding Fotivda (tivozanib) to Opdivo (nivolumab) was shown to have comparable patient-reported outcomes (PROs) versus Fotivda monotherapy for the treatment of locally advanced […]

For patients with low- to intermediate-risk localized prostate cancer, five-fraction stereotactic body radiotherapy (SBRT) could be a more convenient radiation option compared with traditional radiation therapy techniques, an expert said. Traditional radiation techniques include external beam radiation and brachytherapy, explained

After receiving a diagnosis of cancer, having to manage medical bills can be a challenging task. However, reading through these bills carefully and using tools like tracker spreadsheets can be helpful along the way. As patients with cancer receive medical

When an insurance company says no to covering cancer treatments, patients can make external appeals, which may help them get the coverage they need. The first step patients and caregivers can take includes figuring out the type of insurance they

UGN-102 has shown promising results as a non-surgical alternative for patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. For patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, treatment with the novel UGN-102 has shown better responses versus traditional treatment of

Patients treated for prostate cancer face significantly higher long-term risks of urinary, sexual and secondary complications compared to untreated individuals, emphasizing the need for informed treatment decisions. Prostate cancer treatment was associated with higher rates of complications 12 years after

For patients with cancer who are eligible for Medicare, significant changes are coming to Medicare in 2025. Patients who require expensive drugs may experience the benefit of a cap on out-of-pocket drugs that cost more than $2,000, meaning they won’t

The phase 3 ATOM study will evaluate the use of Kimmtrak compared with observation in patients with non-metastatic uveal melanoma. The first patient was enrolled in a phase 3 trial and was randomly assigned to receive treatment for non-metastatic uveal

FDA Approves Unloxcyt for patients with locally advanced or metastatic cutaneous squamous cell carcinoma, a type of skin cancer. The Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for patients with locally advanced or metastatic cutaneous squamous cell carcinoma,

Ultra-sensitive ctDNA testing detected baseline ctDNA in HR-positive early breast cancer, linking it to larger tumors, higher residual cancer burden and increased recurrence rates after neoadjuvant endocrine therapy. Patients with hormone receptor (HR)-positive early breast cancer who underwent ultra-sensitive tissue-free